Fundraising FoxBiotechnology Value Fund — 2026 Investments
6 investments dated 2026 · listed companies and verified rows first · show all
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Founder)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)Shelby Walker(Chief Legal Officer)inRansi Somaratne(Chief Medical Officer)Andreas Busch(Chief Innovation Officer)in
Co-investorsConvergent VenturesDas & Co.IKJ CapitalOregon Venture FundPhoenix Venture Partnerss16+7 more
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
Co-investorsAdjuvant CapitalBioRock VenturesFlucas VenturesMountain Group CapitalRA CapitalHatteras Venture Partners
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsAltium CapitalHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBlue Owl Capital+1 more
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin Eisenfrats(Founder)inJohn Herr(Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)
Co-investorsMBX CapitalAllied Venture PartnersAlumni VenturesAmboy Street VenturesAurum Venture PartnersBeni Venture Capital+19 more
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen HorowitzVida Venturesabrdn plcForesite CapitalHillhouse InvestmentOmega Funds+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.